Recent developments include the announcement of a merger agreement with Scancell Holdings plc and continued analyst coverage maintaining positive recommendations. The company reported a reduction in full-year loss and progress in clinical programs prior to restructuring.

• Neuphoria announced a merger agreement and financing with Scancell Holdings plc, under which Neuphoria will become a wholly owned subsidiary of Scancell if the merger closes [N1].
• Neuphoria was among the most active stocks pre-market on July 23, 2026, reflecting market interest around the merger announcement [N2].
• HC Wainwright & Co. maintained a buy recommendation on Neuphoria Therapeutics as of December 5, 2025 [N4].
• The company reported a drop in full-year loss as of September 30, 2025, reflecting restructuring and cost management efforts [N6].
• Neuphoria presented Phase 2b data for BNC210 at the ASCP 2025 Annual Meeting, highlighting clinical progress prior to program pause [N8].

Neuphoria’s lead candidate BNC210 demonstrated positive Phase 2b results in PTSD, with the FDA providing feedback on a potential registrational path. The company’s partnerships with Merck and Pfizer include milestone and royalty opportunities, with recent milestone payments received. The proposed merger with Scancell could provide strategic and financial resources to support the development or monetization of Neuphoria’s assets. The company’s strong liquidity position as of June 2026 supports ongoing operations and strategic initiatives. Continued clinical readiness of BNC210 PTSD program preserves potential for future development or partnering.

The Phase 3 trial failure of BNC210 in social anxiety disorder led to program discontinuation and restructuring, including significant reduction of internal R&D and workforce. The planned Phase 2b/3 PTSD trial was not initiated, and future development depends on financing and strategic decisions. The Merck-led alpha7 positive allosteric modulator program experienced termination of a Phase 2 trial due to lack of efficacy, limiting near-term milestone prospects. The proposed merger with Scancell carries execution risk and may result in non-development of Neuphoria’s non-partnered assets. The company’s financial statements are prepared on a going concern basis, reflecting ongoing uncertainty about future funding and operations.

Neuphoria’s moat is primarily based on its proprietary small molecule BNC210 targeting the alpha7 nicotinic acetylcholine receptor and its associated intellectual property portfolio. The company’s partnerships with established pharmaceutical companies such as Merck and Pfizer provide access to development and commercialization resources beyond its internal capabilities. However, the company’s internal R&D has been significantly reduced, and it relies heavily on partner-controlled programs for milestone and royalty income. The proposed merger with Scancell may alter the strategic direction and development focus. The company’s clinical-stage assets and passive economic interests in partnered programs represent potential value, but the lack of active internal development and dependence on external partners limit the strength of its competitive moat.

• Merger Completion Risk: The proposed merger with Scancell is subject to customary closing conditions, including stockholder approvals and financing. There is no assurance the merger will close or on its timing, which creates uncertainty for Neuphoria’s future operations and strategy.
• Dependence on Partnered Programs: Neuphoria relies on partners such as Merck, Pfizer, and Carina Biotech for development and commercialization of key programs. Limited control over these programs and uncertainty about milestone and royalty payments pose financial and operational risks.
• Limited Internal Development: Following restructuring, Neuphoria has significantly reduced internal R&D activities and workforce, maintaining only limited clinical readiness for BNC210 PTSD. This limits the company’s ability to advance programs independently.
• Financial and Going Concern Risks: The company reported a net loss and operates with limited cash reserves. Its financial statements are prepared on a going concern basis, reflecting risks related to raising additional capital and sustaining operations without strategic transactions.

• Neuphoria Therapeutics Inc. is a Delaware clinical-stage biotechnology company focused on CNS disorders, particularly through modulation of the alpha7 nicotinic acetylcholine receptor (alpha7 receptor).
• The company’s lead product candidate is BNC210, an oral selective negative allosteric modulator of the alpha7 receptor, historically developed for social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD).
• The Phase 3 AFFIRM-1 trial for BNC210 in SAD did not meet its primary or secondary endpoints, leading to discontinuation of the SAD program and cancellation of the planned AFFIRM-2 trial.
• The BNC210 PTSD program is clinic-ready but paused pending a strategic transaction; the planned SYMPHONY Phase 2b/3 trial was not initiated.
• Neuphoria maintains limited internal R&D activities focused on the alpha7 receptor negative allosteric modulator portfolio, with most preclinical programs discontinued and only minimal costs to maintain intellectual property.
• The company has partnered programs including a collaboration with Merck on alpha7 receptor positive allosteric modulators (PAMs), with Merck controlling development and commercialization; Merck’s MK-1167 Phase 2 trial was terminated after interim analysis, and MK-4334 completed Phase 1 studies.
• Neuphoria may receive milestone payments and royalties from the Merck collaboration, including a $15 million milestone payment received in early 2025.
• Neuphoria holds passive economic interests in legacy oncology programs, including a KAT6 program licensed to Pfizer and a CAR-T therapy program licensed to Carina Biotech, which is in early clinical trials.
• The company entered a merger agreement with Scancell Holdings plc in July 2026, under which Neuphoria will become a wholly owned subsidiary of Scancell if the merger closes.
• The merger consideration includes conversion of Neuphoria shares into Scancell American Depositary Shares and contingent value rights (CVRs) tied to certain net proceeds from partnered programs and intellectual property monetizations.
• Completion of the merger is subject to customary conditions including stockholder approvals, financing, and minimum cash requirements, with no assurance on timing or completion.
• Neuphoria’s financial snapshot as of June 30, 2026, shows cash and equivalents of approximately $19.9 million, current assets of about $21.1 million, current liabilities of $0.76 million, resulting in a strong current ratio of 27.85 and cash ratio of 26.26.
• For fiscal year ended June 30, 2026, Neuphoria reported revenues of approximately $1.17 million and a net loss of about $13.45 million, with basic and diluted EPS of -3.06 USD per share.
• The company has significantly reduced operating expenses, terminated facility leases, retained only one full-time employee, and relies on consulting and external support to maintain operations.
• Neuphoria’s strategy focuses on completing the merger, preserving cash, maintaining public company and contractual obligations, protecting partnered program value, and maintaining clinical readiness of BNC210 PTSD program.
• The FDA granted Fast Track designation to BNC210 for PTSD and acute treatment of SAD; however, the SAD program is discontinued.
• Risks include the uncertainty of merger completion, dependence on partner-controlled programs for milestone and royalty income, limited internal development activities, and the need for additional financing to continue operations or development.
• The company’s financial statements are prepared on a going concern basis, with management assessing strategic alternatives following negative Phase 3 results.
• Neuphoria’s partnered programs and legacy assets provide potential milestone and royalty income but are controlled by third parties, limiting Neuphoria’s direct development influence.